Chinook Therapeutics Raises $106M in Funding
Summary
Chinook Therapeutics, Inc., a Vancouver, British Columbia and Seattle, Washington, WA-based clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, raised $106m in funding. Proceeds from the financing will fund the advancement of the combined company’s pipeline, including: Led by Eric Dobmeier, president and chief executive officer, Chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for kidney diseases. The company’s products are focused on rare, severe chronic kidney disorders with opportunities for well-defined and streamlined clinical pathways. Its lead program is atrasentan, an investigational endothelin receptor antagonist in development for the treatment of IgA nephropathy and other primary glomerular diseases. Through the proposed Aduro merger, Chinook will also add BION-1301, an investigational anti-APRIL monoclonal antibody in a phase 1b trial for IgA nephropathy, to its pipeline.